Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.
Dominik KoeditzJuergen FrenschMartin BierbaumNils-Henning NessBenjamin EttleUmakanth VudumulaKapil GudalaNicholas AdlardSantosh TiwariTjalf ZiemssenPublished in: Multiple sclerosis journal - experimental, translational and clinical (2022)
Immediate OMB treatment and an early switch improves clinical and productivity outcomes while remaining almost cost neutral compared to late or no switches.